2026 Q2 - tulosraportti
62 päivää sitten
‧48 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 200 | - | - | ||
| 140 | - | - | ||
| 1 200 | - | - | ||
| 250 | - | - | ||
| 150 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 22.7. | ||
2026 Q1 - tulosraportti 23.4. | ||
2025 Q4 - tulosraportti 11.2. | ||
2025 Q3 - tulosraportti 30.10.2025 | ||
2025 Q2 - tulosraportti 17.7.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·13 t sittenThose of us who are long-term investors stick to the facts and await the decision in December. If one wants to top up, it is appropriate to do so now. It can of course continue to go down a bit more, but on Wednesday we face a further step in the process. https://swedenbio.se/kalendarium/lsx-congress-usa/ LSX in Boston, Hansa Biopharma participates on Wednesday in LSX Congress USA. It is one of the most significant international congresses for business development, investments, and strategic partnerships within the life science sector. The main purpose of LSX is to arrange exclusive one-on-one meetings between the management of biotech companies and American institutional investors as well as potential pharmaceutical partners Platform for new gene therapy agreements: Since LSX USA gathers global executives in business development (Business Development), it is precisely here that Hansa will pitch imlifidase to new gene therapy companies – in line with the goal of finding more collaborations beyond Sarepta, Genethon, and AskBio My conclusion is that a short-term decline does not mean that the share price during one week in September dictates the share price in December. Another conclusion is that someone who sits and draws lines on their computer can continue to dream that it is their lines and not the market that controls the price… Now I will not spend more time on negative individuals, we look forward to the journey towards December and future collaborations in gene therapy. I https://news.cision.com/se/hansa-biopharma-ab/r/hansa-biopharma-deltar-i-lsx-congress-usa-i-boston,c4398924
13 min sittenWith 22 procent in Hansa, one might think you were a little bias ;) Good luck
·3 päivää sitten · MuokattuIt's just unbelievable how it just keeps falling and falling price 48 early September and now 36 = 25% down
·3 päivää sittenWill it turn up soon as all 🚀 dreams wish? My opinion and not advice 👇- ·16.9.Dilution ? A potential private placement in connection with a listing in the USA could lead to a dilution of 20%, I have compared with Calliditas IPO in the USA. Market conditions are likely to affect a potential discount. I estimate that they might make a decision on the listing some month after the extraordinary general meeting. My opinion and not advice.Good that you now bring up Calliditas as an example, You omit important facts. Perhaps you should write a bit about what happened to Calliditas afterwards. Since you omit this, I will add it. . Calliditas' management is now in Hansas' management. The history - I was myself part of the journey with an initial average cost of 57. Calliditas was then sold. Bid price: 208 kronor cash per share (as well as 416 kronor per American Depositary Share, ADS).Bid premium: The price implied a very high bid premium of 83 percent compared to the closing price the day before the bid was made. Facts and not advice.
·11.9.I've taken a tiny-tiny-micro-position in Glycorex - just to have another small leg in the transplantation market. GAK 1.35. Established on the market but uncertain if there is a profitable market for them. They are struggling a bit to scale the business - now we'll see. Remember, buy only based on your own analyses- I have Hansa at GAK 90+ 😝
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 61 195 | 61 195 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 61 195 | 61 195 | 0 | 0 |
2026 Q2 - tulosraportti
62 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·13 t sittenThose of us who are long-term investors stick to the facts and await the decision in December. If one wants to top up, it is appropriate to do so now. It can of course continue to go down a bit more, but on Wednesday we face a further step in the process. https://swedenbio.se/kalendarium/lsx-congress-usa/ LSX in Boston, Hansa Biopharma participates on Wednesday in LSX Congress USA. It is one of the most significant international congresses for business development, investments, and strategic partnerships within the life science sector. The main purpose of LSX is to arrange exclusive one-on-one meetings between the management of biotech companies and American institutional investors as well as potential pharmaceutical partners Platform for new gene therapy agreements: Since LSX USA gathers global executives in business development (Business Development), it is precisely here that Hansa will pitch imlifidase to new gene therapy companies – in line with the goal of finding more collaborations beyond Sarepta, Genethon, and AskBio My conclusion is that a short-term decline does not mean that the share price during one week in September dictates the share price in December. Another conclusion is that someone who sits and draws lines on their computer can continue to dream that it is their lines and not the market that controls the price… Now I will not spend more time on negative individuals, we look forward to the journey towards December and future collaborations in gene therapy. I https://news.cision.com/se/hansa-biopharma-ab/r/hansa-biopharma-deltar-i-lsx-congress-usa-i-boston,c439892413 min sittenWith 22 procent in Hansa, one might think you were a little bias ;) Good luck
- ·3 päivää sitten · MuokattuIt's just unbelievable how it just keeps falling and falling price 48 early September and now 36 = 25% down
- ·3 päivää sittenWill it turn up soon as all 🚀 dreams wish? My opinion and not advice 👇
- ·16.9.Dilution ? A potential private placement in connection with a listing in the USA could lead to a dilution of 20%, I have compared with Calliditas IPO in the USA. Market conditions are likely to affect a potential discount. I estimate that they might make a decision on the listing some month after the extraordinary general meeting. My opinion and not advice.Good that you now bring up Calliditas as an example, You omit important facts. Perhaps you should write a bit about what happened to Calliditas afterwards. Since you omit this, I will add it. . Calliditas' management is now in Hansas' management. The history - I was myself part of the journey with an initial average cost of 57. Calliditas was then sold. Bid price: 208 kronor cash per share (as well as 416 kronor per American Depositary Share, ADS).Bid premium: The price implied a very high bid premium of 83 percent compared to the closing price the day before the bid was made. Facts and not advice.
- ·11.9.I've taken a tiny-tiny-micro-position in Glycorex - just to have another small leg in the transplantation market. GAK 1.35. Established on the market but uncertain if there is a profitable market for them. They are struggling a bit to scale the business - now we'll see. Remember, buy only based on your own analyses- I have Hansa at GAK 90+ 😝
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 200 | - | - | ||
| 140 | - | - | ||
| 1 200 | - | - | ||
| 250 | - | - | ||
| 150 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 22.7. | ||
2026 Q1 - tulosraportti 23.4. | ||
2025 Q4 - tulosraportti 11.2. | ||
2025 Q3 - tulosraportti 30.10.2025 | ||
2025 Q2 - tulosraportti 17.7.2025 |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 61 195 | 61 195 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 61 195 | 61 195 | 0 | 0 |
2026 Q2 - tulosraportti
62 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 22.7. | ||
2026 Q1 - tulosraportti 23.4. | ||
2025 Q4 - tulosraportti 11.2. | ||
2025 Q3 - tulosraportti 30.10.2025 | ||
2025 Q2 - tulosraportti 17.7.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·13 t sittenThose of us who are long-term investors stick to the facts and await the decision in December. If one wants to top up, it is appropriate to do so now. It can of course continue to go down a bit more, but on Wednesday we face a further step in the process. https://swedenbio.se/kalendarium/lsx-congress-usa/ LSX in Boston, Hansa Biopharma participates on Wednesday in LSX Congress USA. It is one of the most significant international congresses for business development, investments, and strategic partnerships within the life science sector. The main purpose of LSX is to arrange exclusive one-on-one meetings between the management of biotech companies and American institutional investors as well as potential pharmaceutical partners Platform for new gene therapy agreements: Since LSX USA gathers global executives in business development (Business Development), it is precisely here that Hansa will pitch imlifidase to new gene therapy companies – in line with the goal of finding more collaborations beyond Sarepta, Genethon, and AskBio My conclusion is that a short-term decline does not mean that the share price during one week in September dictates the share price in December. Another conclusion is that someone who sits and draws lines on their computer can continue to dream that it is their lines and not the market that controls the price… Now I will not spend more time on negative individuals, we look forward to the journey towards December and future collaborations in gene therapy. I https://news.cision.com/se/hansa-biopharma-ab/r/hansa-biopharma-deltar-i-lsx-congress-usa-i-boston,c439892413 min sittenWith 22 procent in Hansa, one might think you were a little bias ;) Good luck
- ·3 päivää sitten · MuokattuIt's just unbelievable how it just keeps falling and falling price 48 early September and now 36 = 25% down
- ·3 päivää sittenWill it turn up soon as all 🚀 dreams wish? My opinion and not advice 👇
- ·16.9.Dilution ? A potential private placement in connection with a listing in the USA could lead to a dilution of 20%, I have compared with Calliditas IPO in the USA. Market conditions are likely to affect a potential discount. I estimate that they might make a decision on the listing some month after the extraordinary general meeting. My opinion and not advice.Good that you now bring up Calliditas as an example, You omit important facts. Perhaps you should write a bit about what happened to Calliditas afterwards. Since you omit this, I will add it. . Calliditas' management is now in Hansas' management. The history - I was myself part of the journey with an initial average cost of 57. Calliditas was then sold. Bid price: 208 kronor cash per share (as well as 416 kronor per American Depositary Share, ADS).Bid premium: The price implied a very high bid premium of 83 percent compared to the closing price the day before the bid was made. Facts and not advice.
- ·11.9.I've taken a tiny-tiny-micro-position in Glycorex - just to have another small leg in the transplantation market. GAK 1.35. Established on the market but uncertain if there is a profitable market for them. They are struggling a bit to scale the business - now we'll see. Remember, buy only based on your own analyses- I have Hansa at GAK 90+ 😝
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 200 | - | - | ||
| 140 | - | - | ||
| 1 200 | - | - | ||
| 250 | - | - | ||
| 150 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 61 195 | 61 195 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 61 195 | 61 195 | 0 | 0 |